

Ref. No. JPL/CS/1474/2017

Date : 6<sup>th</sup> December, 2017.

To  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
**Mumbai - 400 001.**

Sub. : **Newspapers Publication of unaudited financial Results  
for the quarter and half year ended on 30/09/2017.**

Dear Sir,


Kindly find enclosed, cuttings of following two newspapers dated 06.12.2017 containing the unaudited financial results of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2017.

1. The Free Press Journal, Mumbai - English.
2. Navshakti, Mumbai - Marathi.

Kindly acknowledge.

Thanking you,

Yours faithfully,  
For JENBURKT PHARMACEUTICALS LTD.



ASHISH SHAH  
Company Secretary.

Encl : As Above.

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE  
QUARTER AND HALF YEAR ENDED ON 30/09/2017**

(Rs. in Lacs except EPS)

	Particulars	Quarter ended 30.09.17	Half Year ended 30.09.17	Quarter ended 30.09.16
		(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from Operations (Net)	3769.02	5579.52	2932.30
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extra ordinary items)	1287.26	995.99	700.17
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extra ordinary items)	1287.26	995.99	700.17
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extra ordinary items)	997.30	709.36	506.05
5.	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period after tax and other Comprehensive Income (after tax)	1018.01	730.07	520.53
6.	Paid-up Equity Share Capital (face value of Rs.10/- each)	464.93	464.93	464.93
7.	Reserves and surplus (excluding revaluation reserve as shown in the balance Sheet of the Previous Year)	-	-	-
8.	Earnings per share (EPS) (face value of Rs.10/- each) (for continuing & discontinued operations) (Basic & Diluted)	21.90	15.70	11.20

**NOTES:**

- The above is an extract of the detailed format of Unaudited Financial Results for the Quarter and Half Year ended on 30th September, 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Half Year ended on 30th September, 2017 are available on the website of the Stock Exchange viz. www.bseindia.com and that of the Company viz. www.jenburkt.com.
- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued thereunder, from April 01, 2017. The Company has adopted all required standards under the IND AS and adoption were carried out in accordance with IND AS 101, first time adoption of IND AS. These unaudited financial result including figures for the quarter and Half Year ended 30th September, 2017, have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- The financial results and other financial information for the quarter ended 30th September, 2017 have not been audited by the Statutory Auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- Reconciliation of net profit for the Quarter and Half Year ended 30th September, 2016, as per previous GAAP and IND is as under:

Particulars	Profit Reconciliation for Quarter ended 30.09.16	Profit Reconciliation for Half Year ended 30.09.16
Net Profit for the quarter as per Previous GAAP	503.00	697.95
ADD / (LESS): Adjustment of difference between figures as per GAAP and IND AS		
Deferment of Revenue Recognition	0.47	0.95
Impact of Deferred Tax	0.57	0.03
Discounting of Rent Deposit	-0.87	-1.03
Others	2.89	2.89
Net Profit for the quarter as per IND AS	506.06	700.79

- Reconciliation of equity for the Quarter ended 30th September 2016, as per previous GAAP and INDAS is as under:

Particulars	Equity Reconciliation for the Quarter ended 30.09.2016
Net Equity as per previous GAAP	4719.71
ADD / (LESS): Adjustment of difference between figures as per GAAP and IND AS	
Adjustment due to valuation of Investment at market value through OCI	67.42
Deferment of Revenue Recognition	0.95
Impact of Deferred Tax	0.03
Discounting of Rent Deposit	-1.03
Net Equity for the quarter as per IND AS	4787.08

- The Company is dealing exclusively in Pharmaceuticals formulation segment, hence segment wise reporting is not applicable.
- The figures of the previous periods have been re-grouped, re-cast to render them comparable with figures of the current period.

By order of the Board  
For JENBURKT PHARMACEUTICALS LTD.

Place: Mumbai  
Date: 05/12/2017

(Ashish U. Bhuta)  
Chairman & Managing Director



नवशक्ति

मुंबई, बुधवार, ६ डिसेंबर २०१७

JENBURKT

JENBURKT PHARMACEUTICALS LTD.

Regd. Office: Nirmala Apartments., 93, J. P. Road, Andheri (W), Mumbai-400058  
CIN: L24230MH1985PLC036541 + Tel:66943121 + Fax:66943127 + E-mail: investor@jenburkt.com

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE  
QUARTER AND HALF YEAR ENDED ON 30/09/2017**

(Rs. in Lacs except EPS)

Particulars	Quarter ended 30.09.17	Half Year ended 30.09.17	Quarter ended 30.09.16
	(Unaudited)	(Unaudited)	(Unaudited)
1. Total Income from Operations (Net)	3769.02	5579.52	2932.30
2. Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extra ordinary items)	1287.26	995.99	700.17
3. Net Profit / (Loss) for the period before tax (after Exceptional and/or Extra ordinary items)	1287.26	995.99	700.17
4. Net Profit / (Loss) for the period after tax (after Exceptional and/or Extra ordinary items)	997.30	709.36	506.05
5. Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period after tax and other Comprehensive Income (after tax)	1018.01	730.07	520.53
6. Paid-up Equity Share Capital (face value of Rs.10/- each)	464.93	464.93	464.93
7. Reserves and surplus (excluding revaluation reserve as shown in the balance Sheet of the Previous Year)	-	-	-
8. Earnings per share (EPS) (face value of Rs.10/- each) (for continuing & discontinued operations) (Basic & Diluted)	21.90	15.70	11.20

**NOTES:**

- The above is an extract of the detailed format of Unaudited Financial Results for the Quarter and Half Year ended on 30th September, 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Half Year ended on 30th September, 2017 are available on the website of the Stock Exchange viz. www.bseindia.com and that of the Company viz. www.jenburkt.com.
- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued thereunder, from April 01, 2017. The Company has adopted all required standards under the IND AS and adoption were carried out in accordance with IND AS 101, first time adoption of IND AS. These unaudited financial result including figures for the quarter and Half Year ended 30th September, 2017, have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- The financial results and other financial information for the quarter ended 30th September, 2017 have not been audited by the Statutory Auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- Reconciliation of net profit for the Quarter and Half Year ended 30th September, 2016, as per previous GAAP and IND is as under:

Particulars	Profit Reconciliation for Quarter ended 30.09.16	Profit Reconciliation for Half Year ended 30.09.16
Net Profit for the quarter as per Previous GAAP	503.00	697.95
ADD / (LESS): Adjustment of difference between figures as per GAAP and IND AS		
Deferment of Revenue Recognition	0.47	0.95
Impact of Deferred Tax	0.57	0.03
Discounting of Rent Deposit	-0.87	-1.03
Others	2.89	2.89
Net Profit for the quarter as per IND AS	506.06	700.79

- Reconciliation of equity for the Quarter ended 30th September 2016, as per previous GAAP and IND AS is as under:

Particulars	Equity Reconciliation for the Quarter ended 30.09.2016
Net Equity as per previous GAAP	4719.71
ADD / (LESS): Adjustment of difference between figures as per GAAP and IND AS	
Adjustment due to valuation of Investment at market value through OCI	67.42
Deferment of Revenue Recognition	0.95
Impact of Deferred Tax	0.03
Discounting of Rent Deposit	-1.03
Net Equity for the quarter as per IND AS	4787.08

- The Company is dealing exclusively in Pharmaceuticals formulation segment, hence segment wise reporting is not applicable.
- The figures of the previous periods have been re-grouped, re-cast to render them comparable with figures of the current period.

By order of the Board  
For JENBURKT PHARMACEUTICALS LTD.

Place: Mumbai  
Date: 05/12/2017

(Ashish U. Bhuta)  
Chairman & Managing Director